Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Shimato, S; Maier, LM; Maier, R; Bruce, JN; Anderson, RC; Anderson, DE.
Profound tumor-specific Th2 bias in patients with malignant glioma.
BMC Cancer. 2012; 12(4):561-561 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Maier Richard

Dimensions Citations:

Plum Analytics:
Number of Figures: 4
| | | |
Background: Vaccination against tumor-associated antigens is one promising approach to immunotherapy against malignant gliomas. While previous vaccine efforts have focused exclusively on HLA class I-restricted peptides, class II-restricted peptides are necessary to induce CD4(+) helper T cells and sustain effective anti-tumor immunity. In this report we investigated the ability of five candidate peptide epitopes derived from glioma-associated antigens MAGE and IL-13 receptor alpha 2 to detect and characterize CD4(+) helper T cell responses in the peripheral blood of patients with malignant gliomas. Methods: Primary T cell responses were determined by stimulating freshly isolated PBMCs from patients with primary glioblastoma (GBM) (n = 8), recurrent GBM (n = 5), meningioma (n = 7), and healthy controls (n = 6) with each candidate peptide, as well as anti-CD3 monoclonal antibody (mAb) and an immunodominant peptide epitope derived from myelin basic protein (MBP) serving as positive and negative controls, respectively. ELISA was used to measure IFN-gamma and IL-5 levels, and the ratio of IFN-gamma/IL-5 was used to determine whether the response had a predominant Th1 or Th2 bias. Results: We demonstrate that novel HLA Class-II restricted MAGE-A3 and IL-13R alpha 2 peptides can detect T cell responses in patients with GBMs as well as in healthy subjects. Stimulation with a variety of peptide antigens over-expressed by gliomas is associated with a profound reduction in the IFN-gamma/IL-5 ratio in GBM patients relative to healthy subjects. This bias is more pronounced in patients with recurrent GBMs. Conclusions: Therapeutic vaccine strategies to shift tumor antigen-specific T cell response to a more immunostimulatory Th1 bias may be needed for immunotherapeutic trials to be more successful clinically.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Antigens, Neoplasm - immunology
Brain Neoplasms - blood
Cytokines - analysis
Enzyme-Linked Immunosorbent Assay -
Epitopes, T-Lymphocyte - immunology
Female -
Glioma - blood
Histocompatibility Antigens Class II - immunology
Humans -
Male -
Middle Aged -
Th2 Cells - immunology

© Meduni Graz Impressum